Nouv

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo expects to complete Biological License Application (BLA) submission under accelerated approval pathway in second quarter of 2026

Évén

Alberta (Canmore) Patient empowerment meeting and Youth & young adult summit

Our Patient empowerment meeting, and our Youth & Young adult summit will be in Canmore, Alberta this year.

Évén

Ontario meeting sign up

Sign up for the Ontario Patient empowerment meeting